Compounding Pharmacies and Ketamine: What Patients Should Know

The Role of Compounding Pharmacies in Ketamine Therapy

Compounding pharmacies play an essential role in the current landscape of ketamine therapy. Because the only commercially manufactured ketamine products are generic injectable solutions (approved for anesthesia) and Spravato nasal spray (approved for depression), virtually all other ketamine formulations — sublingual troches, lozenges, nasal sprays, topical creams, and oral solutions — must be individually prepared by compounding pharmacies according to a prescriber's specifications.

This makes compounding pharmacies a critical link in the ketamine therapy supply chain. The quality, consistency, and safety of the compounded product directly affect the patient's treatment experience and outcomes. Understanding how compounding pharmacies operate, how they are regulated, and how to evaluate their quality is valuable knowledge for patients receiving compounded ketamine.

What Is Pharmacy Compounding?

Definition

Pharmacy compounding is the practice of preparing customized medications to meet individual patient needs. Unlike mass-manufactured pharmaceuticals, which are produced in large batches according to standardized FDA-approved formulations, compounded medications are made in smaller quantities according to a specific prescription or clinical protocol.

Compounding allows for:

• Custom dosage forms not commercially available (e.g., ketamine troches)
• Specific dose strengths tailored to individual patients
• Removal of allergens or inactive ingredients that a patient cannot tolerate
• Combination of multiple active ingredients in a single formulation
• Flavoring to improve palatability

Historical Context

Pharmacy compounding has existed since the earliest days of pharmacy — for centuries, pharmacists prepared most medications from raw ingredients. The rise of large-scale pharmaceutical manufacturing in the 20th century reduced the need for routine compounding, but it has experienced a resurgence as personalized medicine has grown and as demand for non-commercial formulations (like psychiatric ketamine) has increased.

Types of Compounding Pharmacies

503A Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act defines traditional compounding pharmacies that prepare medications based on individual patient prescriptions. These pharmacies:

• Compound pursuant to a valid prescription for an identified individual patient
• Are primarily regulated by state boards of pharmacy
• Are not required to register with the FDA (though the FDA retains enforcement authority)
• Must comply with applicable USP compounding standards
• Generally prepare smaller quantities

503B Outsourcing Facilities

Section 503B, established by the Drug Quality and Security Act of 2013, created a category of outsourcing facilities that can compound larger quantities of medications without individual patient prescriptions. These facilities:

• Must register with the FDA and are subject to FDA inspection
• Must comply with Current Good Manufacturing Practice (cGMP) requirements
• Can distribute compounded medications to healthcare facilities and providers without patient-specific prescriptions
• Are subject to more rigorous quality and reporting requirements than 503A pharmacies

Many of the larger ketamine compounding operations function as 503B outsourcing facilities, allowing them to prepare and ship ketamine formulations at scale to telehealth companies and clinics nationwide.

Quality Considerations

Potency and Consistency

One of the most critical quality concerns with compounded medications is potency accuracy — whether the compounded product contains the correct amount of active ingredient. Published analyses of compounded medications have found that some products deviate significantly from the labeled potency, meaning patients could receive more or less medication than intended.

For ketamine, potency variability is particularly consequential because the therapeutic dose range is relatively narrow for psychiatric use, and both under-dosing (insufficient therapeutic effect) and over-dosing (excessive dissociation, cardiovascular effects) can occur.

Quality pharmacies mitigate this risk through:

• Analytical testing (such as high-performance liquid chromatography) to verify potency
• Beyond-use date testing to confirm stability over the product's shelf life
• Documented standard operating procedures for each formulation
• Regular calibration of compounding equipment

Sterility (Where Applicable)

Ketamine formulations intended for injection (IM or IV) must be prepared under sterile conditions. Contaminated injectable products pose serious infection risks. Sterile compounding must comply with USP <797> standards, which specify requirements for personnel training, environmental controls, equipment, and quality testing.

Non-sterile formulations (troches, lozenges, creams) must comply with USP <795> standards, which are less stringent than sterile compounding requirements but still mandate specific quality controls.

Stability and Beyond-Use Dating

Beyond-use dates (BUDs) indicate the period during which a compounded product is expected to maintain its potency and quality. These are different from expiration dates on commercial products and must be supported by stability testing data. Patients should check the BUD on their compounded ketamine and not use the product beyond this date.

Regulatory Oversight

State Pharmacy Boards

State boards of pharmacy are the primary regulators of 503A compounding pharmacies. Their oversight includes:

• Licensing and renewal of pharmacy permits
• Inspection of facilities and operations
• Investigation of complaints and adverse event reports
• Enforcement of state pharmacy laws and regulations
• Disciplinary actions for non-compliance

The rigor of state oversight varies, with some states maintaining robust inspection programs and others operating with fewer resources.

FDA Oversight

The FDA's role differs for 503A and 503B pharmacies:

• 503A: The FDA generally exercises enforcement discretion and does not routinely inspect these pharmacies, though it retains the authority to take action if safety concerns arise
• 503B: The FDA actively inspects outsourcing facilities and can take enforcement action, including warning letters, injunctions, and recalls, for cGMP violations

USP Standards

The United States Pharmacopeia publishes the compounding standards that pharmacies must follow:

• USP <795>: Standards for non-sterile compounding
• USP <797>: Standards for sterile compounding
• USP <800>: Standards for handling hazardous drugs
• USP <825>: Standards for radiopharmaceuticals (not typically relevant to ketamine)

Compliance with these standards is expected by state boards of pharmacy and the FDA.

How to Evaluate a Compounding Pharmacy

Patients and prescribers can evaluate a compounding pharmacy using the following criteria:

Accreditation

The Pharmacy Compounding Accreditation Board (PCAB), a service of the Accreditation Commission for Health Care, provides voluntary accreditation for compounding pharmacies. PCAB accreditation indicates that a pharmacy has met standards for quality, safety, and operational excellence. While accreditation is not mandatory, it is a strong indicator of quality.

Third-Party Testing

Some pharmacies voluntarily submit their products for independent third-party testing to verify potency and purity. Pharmacies that can provide certificates of analysis from independent laboratories offer a higher level of quality assurance.

Transparency

Quality pharmacies are willing to provide information about their compounding processes, quality testing, sourcing of raw materials, and compliance with USP standards. Reluctance to share this information may be a red flag.

Communication

Pharmacies that maintain open communication with prescribers — including reporting any concerns about prescriptions, providing consultation on formulation options, and alerting prescribers to potential issues — demonstrate a commitment to collaborative patient care.

Choosing Between Pharmacies

When multiple pharmacy options are available, factors to consider include:

• PCAB accreditation or equivalent quality credentials
• Availability of potency and stability testing data
• Compliance with current USP standards
• Reputation among prescribers and patients
• Willingness to provide documentation of quality controls
• Customer service and communication responsiveness
• Shipping practices (temperature control, packaging integrity)
• Pricing transparency

Note: This article is for educational purposes only and does not constitute medical or pharmaceutical advice. Patients should work with their prescribing provider to select an appropriate compounding pharmacy and should direct questions about specific compounded products to their pharmacist or prescriber.

References

• FDA: Drug Information — FDA resource on drug compounding regulations, 503A/503B pharmacy oversight, and safety communications
• StatPearls: Ketamine — Clinical reference covering ketamine formulations and pharmaceutical preparation standards
• Ketamine Pharmacology: An Update — NIH review of ketamine pharmacology including formulation considerations and quality standards
• MedlinePlus: Ketamine Injection — National Library of Medicine information on commercially manufactured ketamine products